Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization

References

• Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–770.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739.
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171.
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155–2166.
   PubMed Web of Science ®Google Scholar
• Malek NP, Schmidt S, Huber P, et al. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int. 2014;111:101–106.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
   PubMed Web of Science ®Google Scholar
• Reig M, Darnell A, Forner A, et al. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis. 2014;34:444–455.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187–1195.
   PubMed Web of Science ®Google Scholar
• Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolization for hepatocellular cancer. Ann Oncol. 2013;24:2565–2570.
   PubMed Web of Science ®Google Scholar
• Park Y, Kim SU, Kim BK, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36:100–107.
   PubMed Web of Science ®Google Scholar
• Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014;61:1287–1296.
   PubMed Web of Science ®Google Scholar
• Cappelli A, Cucchetti A, Cabibbo G, et al. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36:729–736.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013;57:2261–2273.
   PubMed Web of Science ®Google Scholar
• Adhoute X, Penaranda G, Naude S, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2015;62:855–862.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Weinmann A, Koch S, Sprinzl M, et al. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015;35:591–600.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442.
   PubMed Web of Science ®Google Scholar
• Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolization for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;CD004787.
   Google Scholar
• Ogasawara S, Chiba T, Ooka Y, et al. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. PLoS One. 2015;10:e0125244.
   Google Scholar
• Ha Y, Han S, Shim JH, et al. Nomograms for predicting outcomes after chemoembolization in patients with nonmetastatic hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26:1093–1101. e1091.
   PubMed Web of Science ®Google Scholar
• Kim BK, Shim JH, Kim SU, et al. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2016;36:92–99.
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011;48:155–170.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Yuasa T, Maita S, et al. Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma. BMC Urol. 2014;14:26.
   PubMed Web of Science ®Google Scholar
• Mitsunaga S, Ikeda M, Shimizu S, et al. C-reactive protein level is an indicator of the aggressiveness of advanced pancreatic cancer. Pancreas. 2016;45:110–116.
   PubMed Web of Science ®Google Scholar
• Hucke F, Sieghart W, Pinter M, et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;60:118–126.
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Tateishi R, Nakagawa H, et al. Slight elevation of high-sensitivity C-reactive protein to predict recurrence and survival in patients with early stage hepatitis C-related hepatocellular carcinoma. Hepatol Res. 2015;45:645–655.
   PubMed Web of Science ®Google Scholar
• Kohles N, Nagel D, Jungst D, et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumor Biol. 2012;33:33–40.
   PubMed Web of Science ®Google Scholar
• Takeda H, Nishikawa H, Iguchi E, et al. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol. 2013;1:241–248.
   PubMedGoogle Scholar
• Kaibori M, Matsui K, Saito T, et al. Risk factors for early death due to recurrence after resection of large hepatocellular carcinomas. Hepatogastroenterology. 2008;55:2151–2156.
   PubMed Web of Science ®Google Scholar
• Dettmer A, Kirchhoff TD, Gebel M, et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol. 2006;12:3707–3715.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Amarapurkar D, Chao Y, et al. Reevaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an international expert panel. Liver Int. 2014;34:174–183.
   PubMed Web of Science ®Google Scholar
• Georgiades C, Geschwind JF, Harrison N, et al. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology. 2012;265:115–123.
   PubMed Web of Science ®Google Scholar